AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024
Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
FDA grants full approval for TIVDAK to treat cervical cancer
Granules India announced ANDA Approval for Colchicine Capsules
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data
Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall
Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development
Glenmark receives ANDA approval for acetaminophen and ibuprofen tablets
AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants
Implementing a digital transformation in chemical operations to maximize profitability
The complexity of compliance
The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation
The guiding role of fluidized and spouted bed technologies in particle building processes